We are currently running a pivotal study assessing frunevetmab at approximately 20 clinics around the United States. For more information, including how to enrol your cat, see the bottom of this page.
Like ranevetmab, frunevetmab is an anti-NGF monoclonal antibody (mAb). Nexvet is developing frunevetmab as a treatment for the control of pain associated with osteoarthritis in cats.
Like ranevetmab, frunevetmab inhibits the activity of nerve growth factor (NGF), a mediator of pain signaling and nerve growth. You can read more about NGF on the ranevetmab page.
As a PETized mAb, frunevetmab is “100% species-specific”, meaning it has been designed to be recognized by the feline immune system as “native”, reducing the likelihood of an adverse “immunogenic” immune reaction in cats.
In 2016, Nexvet received notification from the United States Adopted Name (USAN) Council that it had approved the generic name “frunevetmab” for NV-02, its former name.
Frunevetmab is currently undergoing a pivotal field efficacy and safety study which will enrol approximately 250 cats with osteoarthritis at approximately 20 clinical sites around the United States. If you are interested in enrolling your cat in this study, see the information at the bottom of this page.
In a multi-center, placebo-controlled, randomized, double-blind field study which enrolled 126 cats with osteoarthritis at 15 sites in the United States, frunevetmab demonstrated statistically significant efficacy over placebo at multiple timepoints, using multiple assessment methods. No significant adverse safety signals were observed in this study.
In a previous proof-of-concept efficacy study of 34 client-owned cats with degenerative joint disease, frunevetmab demonstrated statistically significant improvements over placebo using two measures. This study was described in the peer-reviewed Journal of Veterinary Internal Medicine.
The PETization of frunevetmab and an early demonstration of its efficacy in reducing lameness in a model of acute inflammatory pain are described in another paper in the Journal of Veterinary Internal Medicine.
Frunevetmab has been found to be safe and well-tolerated following subcutaneous injection and intravenous infusion in cats. It has also demonstrated statistically significant improvements in activity levels over placebo up to 5 weeks after a subcutaneous injection.
You may find at this link a presentation summarizing the clinical studies of frunevetmab, with particular focus on the design and outcomes of its pilot field efficacy and safety study which enrolled 126 cats. This presentation was given to an audience of 242 attendees of the American College of Veterinary Internal Medicine (ACVIM) Forum, in June 2016.
There are approximately 85.8 million pet cats in the United States, and various clinical studies have indicated that a majority of cats show radiographic evidence of degenerative joint disease (DJD). DJD is a term encompassing various conditions including osteoarthritis, although the two terms are often used interchangeably. Osteoarthritis incidence increases with age, and a major industry survey conducted by Banfield showed that the average lifespan of the U.S. pet cat population increased 10% in the decade from 2002 to 2012.
In the United States, there are no drugs approved for chronic pain management in cats. The use of non-steroidal anti-inflammatory drugs (NSAIDs) for acute pain management has not translated into NSAIDs approved for long-term use as cats lack key drug detoxification pathways in their livers and are susceptible to renal toxicity. On the whole, only 20% of veterinarians participating in a recent industry survey were satisfied with pain management choices (including acute and chronic options) for cats. mAbs are not metabolized by the liver or kidneys and therefore are not expected to have side effects connected to these organs.
Cats are also often reported as being resistant to oral dosing, making a long-lasting and easily administered option highly desirable for cats, owners, and veterinarians.
We believe the introduction of a safe and effective pain management product class (such as anti-NGF mAbs in a monthly subcutaneous injectable formulation) has the potential to meet a sizeable medical need in feline medicine and be a first-mover in this space.
Between 86% and 98% of 390 veterinarian respondents in a proprietary survey indicated they would use a product such as frunevetmab for the treatment of chronic pain in cats.